Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lose momentum if future growth does not justify high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: Pediatrix Medical Group (MD) Analysis - Pediatrix Medical Group (MD) has shown a price increase of 1.4% over the past four weeks, indicating growing investor interest [4] - The stock has gained 4.4% over the past 12 weeks, with a beta of 1.49, suggesting it moves 49% more than the market [5] - MD has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to MD earning a Zacks Rank 1 (Strong Buy), which is associated with strong momentum effects [7] - MD is trading at a Price-to-Sales ratio of 0.61, suggesting it is undervalued as investors pay only 61 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides MD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stocks based on various investing styles [9]

Shares of Pediatrix Medical Group, Inc. (MD) have soared 37.7% in the past six months, outperforming the industry and sector’s declines of 12.9% and 9.4%, respectively. The S&P 500 Index rose 4.6% in the same time frame. Favorable payer mix and positive patient volume trends should further lead to more price appreciation of this stock.MD’s Six-Month Price PerformanceImage Source: Zacks Investment ResearchGiven the impressive performance so far, can investors still consider buying Pediatrix Medical stock, or ...

Core Viewpoint - Pediatrix Medical Group (MD) has seen a 4.2% increase in stock price over the past four weeks, closing at $14.51, with a potential upside of 25.5% based on Wall Street analysts' mean price target of $18.21 [1] Price Targets - The mean estimate consists of seven short-term price targets with a standard deviation of $1.35, indicating variability among analysts; the lowest estimate suggests a 17.2% increase to $17, while the highest predicts a 44.7% surge to $21 [2][7] - Analysts' price targets can often mislead investors, as empirical research shows that these targets rarely indicate actual stock price movements [5][6] Earnings Estimates - Analysts have shown increasing optimism regarding MD's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 3.5% over the past month, with four estimates increasing and one decreasing [10] Zacks Rank - MD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [11] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they do provide a useful guide for the direction of price movement [12]

Core Insights - Midland Exploration Inc. has initiated a second drilling campaign for lithium at the Galinée project, in partnership with Rio Tinto Exploration Canada Inc. [6] - The Galinée project is strategically located near the Adina lithium deposit, which has significant mineral resources [13] Drilling Program Details - The 2024 drilling program included 21 diamond drill holes and 7 reverse circulation (RC) drill holes, totaling 6,284.86 meters, with 819.92 meters being RC drilling [7] - The main focus was on the Iceberg showing and other areas such as White Stripes, Surge, Snow Fox, and White Lightning [7] - Significant drill results include core length interval composites of 1.38% Li2O over 37.86 meters in hole TLIB0007, and other notable results from holes TLIB0026 and TLIB0018 [7][8] Financial and Operational Plans - A budget of 5.2 million CAD has been approved for the first phase of drilling in 2025, which will commence with RC drilling followed by diamond drilling [9][12] - The drilling will aim to follow up on the best intersections from 2024 and explore structural targets throughout the property [9] Geological Insights - Geological mapping and drilling have identified at least seven spodumene pegmatite bodies, with indications that these bodies are open along strike and to depth [11] - The major lithium phase at Iceberg is identified as spodumene, with minor alterations present [11] Project Context - The Galinée project is located in a favorable geological setting, similar to the Adina deposit, which has a consolidated mineral resource of 61.4 million tons at 1.14% Li2O indicated [13]

Core Insights - Midland Exploration Inc. and SOQUEM Inc. have discovered new copper showings in the Labrador Trough, specifically in the central part of the region, which has been identified as prospective for economic copper mineralization [1][10] - The reconnaissance program in 2024 led to the discovery of several copper occurrences over a distance of 3.7 km, prompting the staking of 104 mining claims [5][9] Exploration Details - A 2-day reconnaissance campaign in early summer 2024 involved collecting 42 rock samples, revealing chalcopyrite mineralization in fractures and quartz-calcite veins within a mafic intrusive of the Wakuach Suite [3][4] - The best grades from the samples included 16 samples with grades greater than 0.1% Cu, with 2 samples exceeding 1% Cu, reaching up to 3.73% Cu [5][6] Mineralization Characteristics - The mineralized samples are distributed along a northwest-southeast-trending magnetic axis, with the major Argencourt thrust fault located 4 km to the west [6][10] - Anomalous values for other elements such as gold, cobalt, and molybdenum were also observed in the samples [5][6] Future Plans - Midland and SOQUEM plan to continue assessing the economic potential of these discoveries in 2025, with surface exploration work including rock and soil sampling [10][14] - The Strategic Alliance between Midland and SOQUEM aims to explore the mineral potential of the Labrador Trough, with a commitment to invest up to $5 million over four years [13][14]

Pediatrix Medical Group, Inc. (MD) shares rose 10.6% since it reported fourth-quarter 2024 results on Feb. 20, 2025. The quarterly results benefited on the back of strong same-unit revenue growth, improved payor mix and higher hospital contract administrative fees. A decline in the overall expense level also contributed to the upside. However, the upside was partly offset by higher same-unit clinical compensation costs.See the Zacks Earnings Calendar to stay ahead of market-making news.MD reported fourth-qu ...

Financial Data and Key Metrics Changes - The company reported adjusted EBITDA of $69 million for Q4 2024, significantly exceeding previous guidance [10] - Consolidated revenue growth was just over 1%, with same unit revenue growth of 8.7%, largely offset by the impact of portfolio restructuring [18] - Operating cash flow for Q4 was $135 million, compared to $73 million in the prior year, with a reduction in net debt from $515 million to $386 million [21][23] Business Line Data and Key Metrics Changes - The portfolio restructuring resulted in exiting practices that represented $200 million in annual revenue, which was a drag on earnings [10] - Same unit cost trends continued to decline compared to the previous quarter, although same unit salary expense growth remains above the historical range of 2% to 3% [20][31] Market Data and Key Metrics Changes - The payer mix was a significant positive factor in 2024, contributing to strong operating results, although it is not expected to change significantly in 2025 [30][61] - The company anticipates flat volume growth in 2025, with NICU days showing just under 3% growth and births up about 30 basis points in Q4 2024 [37] Company Strategy and Development Direction - The company aims to prioritize patient-centric care, strengthen hospital relationships, and manage its improved financial position effectively [13][14] - A preliminary expectation for adjusted EBITDA in 2025 is set between $215 million and $235 million, reflecting a cautious outlook amid uncertainty in the healthcare provider space [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects despite acknowledging headwinds in the healthcare sector [17] - The focus for the first half of 2025 will be on maintaining stability in the revenue cycle management (RCM) process and seeking improvements through automation [29] Other Important Information - The company completed its portfolio restructuring on time, which is expected to yield an annualized EBITDA benefit of approximately $30 million [27][81] - The company ended the year with cash of $230 million and plans to build cash again in 2025 while considering the best course for capital allocation [24][88] Q&A Session Summary Question: Can you provide more details on the 2025 outlook? - Management indicated that they expect flat volume growth in 2025, with a strong payer mix contributing positively in 2024 but anticipated to level off [36][39] Question: Are there opportunities for improved economics in NICU management? - Management confirmed ongoing discussions with hospital partners but did not incorporate any increases into their forecast [44] Question: How much of the pricing strength in Q4 will carry into 2025? - The pricing component was attributed to improvements in contract admin fees, but overall pricing is expected to remain flat [75][77] Question: What are the key areas of optimism for 2025? - Management highlighted the importance of strengthening hospital relationships and improving recruitment as key areas for future success [68][70] Question: What are the plans for capital allocation and returning cash to shareholders? - The company emphasized the importance of a strong balance sheet and will evaluate options for capital allocation as the year progresses [88][90]

Pediatrix Medical Group, Inc. (NYSE:MD) Q4 2024 Earnings Conference Call February 20, 2025 9:00 AM ET Company Participants Charles Lynch - Senior Vice President, Finance & Strategy Mark Ordan - Chief Executive Officer Kasandra Rossi - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants A.J. Rice - UBS Jack Levin - Jefferies Whit Mayo - Leerink Partners Benjamin Shaver - Deutsche Bank Operator Thank you for standing by. My name is Tammy, and I will be your conference op ...

Group 1 - Pediatrix Medical Group reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and up from $0.32 per share a year ago, representing an earnings surprise of 37.84% [1] - The company achieved revenues of $502.36 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.44%, compared to $496.44 million in the same quarter last year [2] - The stock has increased approximately 7.6% since the beginning of the year, outperforming the S&P 500's gain of 4.5% [3] Group 2 - The earnings outlook for Pediatrix Medical Group is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.24 on revenues of $472.5 million, and $1.47 on $1.97 billion in revenues for the current fiscal year [7] - The Medical Services industry, to which Pediatrix belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Group 3 - The company has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] - The current Zacks Rank for Pediatrix Medical Group is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from to Commission file number 001-12111 Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in ...